How ELISA testing and flow cytometry can complement ELISPOT assays
Posted: Thursday, June 14, 2007
by V Berba Velasco Jr PhD
Articles and Stuff
The ELISPOT technique is among the most powerful tools in an immunology researcher’s arsenal. ELISPOT assays are used to determine the number of cells in a blood sample that produce a particular secretion—for example, specific cytokines, antibodies, or granzymes. ELISPOT assays also exhibit exceptional sensitivity, allowing even individual cells to be detected. Such single-cell resolution is possible because the secretory products are captured around the secreting cells before they can be diluted, degraded, or snatched up by neighboring cells. When you need an accurate readout of low frequency immune responses, the ELISPOT assay is the method of choice.
Flow cytometry can likewise be used to provide additional insight into the mechanics of an immune response. ELISPOT assays are exceptionally sensitive at low-frequency response levels—that is, when very few cells produce the desired secretion. In contrast, flow cytometry works best when dealing with high-frequency responses. This makes it an invaluable tool when the cellular responses are excessively large, i.e. too numerous to count using the ELISPOT method.
The bottom line: The ELISPOT assay is exceptionally sensitive and provides unprecedented single-cell resolution, making it a formidable tool for any immunology researcher. There are times, however, when its effectiveness can be further enhanced by using flow cytometry and the ELISA method. When used in concert, these technologies can provide a more comprehensive view of the subject’s immune response.
About the author:
V. B. Velasco Jr is a senior electrical and software engineer at a small biotech company that specializes in immunology research. Its products and services can be used for immunogenicity testing, epitope discovery, and bacterial colony counting, among other applications.
This Article has been viewed 257 times. (Not updated in real-time.)
Top-level comments on this article: (1 total)Very nice and to the point.
We want your comments! If you can read this, you don't have javascript enabled, so you can't use this comment system. Please enable javascript.